Trial Number
493-24
Condition
Epilepsy
Participant Age Range
18 years to 75 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy”
The study is looking at the safety and tolerability of a medication called BHV-7000 for people with focal onset epilepsy.